2型糖尿病患者におけるダパグリフロジン治療の4年後の冠動脈流れの増加: DAPAHEARTフォローアップ研究
Francesca Cinti1, Cassandra Morciano2, Andrea Guarneri3
1Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy. cinti_francesca@hotmail.com.
Cardiovascular diabetology
|August 31, 2025
まとめ
冠動脈疾患の2型糖尿病患者におけるダパグリフロジンの長期治療は,冠動脈の流れの準備を有意に改善し,心臓の脂肪組織を減少させた. ダパグリフロジンの保護作用を示唆する.
科学分野:
- 心臓病科
- 内分泌学
- 薬理学について
背景:
- 2型糖尿病 (T2DM) の心血管疾患による死亡率を低下させる.
- 以前の研究では,短期間SGLT2iを使用すると,冠動脈循環量 (CFR) が改善され,冠動脈動脈疾患 (CAD) のT2DM患者における心臓の脂肪組織 (EAT) が減少することが示されました.
- T2DMとCADにおけるこれらのパラメータに対するSGLT2iの長期的な影響は不明である.
研究 の 目的:
- 安定したCADのT2DM患者におけるCFRとEATの厚さに対するダパグリフロジンの長期的な影響を評価する.
- 短期的な利益が4年間持続するかどうかを評価する.
主な方法:
- DAPAHEART試験は,単一センター,ランダム化,ダブルブラインド,プラセボ対照試験でした.
- T2DMと安定したCADの患者はダパグリフロジン10 mgまたはプラセボを4週間投与し,プラセボ患者は後にダパグリフロジンに移行した.
- 冠動脈流量リザーブ (CFR) と心臓の脂肪組織 (EAT) の厚さは,13N-アンモニアPET/CTを用いて,ベースライン,4週間,4年後に測定された.
主要な成果:
- 4年後,CFRは34. 4% (p=0. 001) 増加し,EATの厚さは29. 18% (p=0. 03) 減少した.
- すべての患者でボディマス指数 (BMI) が低下した (p=0. 001).
- BMIとEATの厚さの変化は有意に相関せず,体重に関係ないEATに対するダパグリフロジンの効果を示唆した.
結論:
- ダパグリフロジン投与の4週間後に観測されたCFRの有意な改善は,4年後に持続した.
- CFRの改善に潜在的に寄与する,EATの厚さの有意な減少も観察されました.
- T2DM患者におけるダパグリフロジンの長期的心臓血管効果を強調しています.
さらに関連する動画
05:07Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice
Published on: August 25, 2023
1.3K
06:39Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
Published on: April 13, 2015
15.1K
関連する概念動画
01:23Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:26Angina IV: Management
22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30